The purpose of this investigation was to study the therapeutic effect of Lamivudine on HBVDNA in peripheral blood mononudear cells （PBMC） and serum, and the level of cytokines in serum of the patients with chronic h...The purpose of this investigation was to study the therapeutic effect of Lamivudine on HBVDNA in peripheral blood mononudear cells （PBMC） and serum, and the level of cytokines in serum of the patients with chronic hepatitis B. The patients were divided into two groups （A = 47, B = 34）, and treated by Lamivudine, routine medicine, respectively. The levels of HBV-DNA in PBMC and serum and eytokines were all detected before and after treatment. After the treatment of Lamivndine for 36 weeks, the total conversion negative rates of HBV-DNA in PBMC and serum of the patients treated with Lamivudine were 55.32% （26/47） and 61.70% （29/47）, respectively. The total negative conversion rates of HBV-DNA in PBMC and serum of the patients treated by routine medicine were 26.47 % （9/34） and 32.35% （11/34）, respectively. There was significant difference between Lamivudine group and routine medicine group （ P 〈 0.01 ）. The negative conversion rates of HBeAg in serum of the patients were 46.81% （22/47） and 68.09% （32/47） at the end of 24 weeks and 36 weeks, and were higher than those of routine medicine group （ P 〈 0.05 and P 〈 0.01 ）. The levels of alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, ALT/AST in serum of the patients after being treated by Lamivudine, routine medicine were down-regulated to （30.1 ± 9.6） U/ml, （32.3 ±10.7） U/ml, 0.9 ±0.1 and （48.4±10.7） U/ml, （44.7 ±11.0） U/ml, 1.1 ±0.2. After the analysis of variance, the high significant difference was obvious between the two groups （ P 〈 0.01）. It was due to the high levels of IL-6, IL-8 and TNF-α in chronic hepatitis B which could be down-regulated to （250.5 ±33.3） pg/ml, （153.4 ±22.2） pg/ml, （232.6 ±21.2） pg/ml by Lamivudine, which was more obvious than that of routine medicine （ P 〈 0.01）. Lamivudine has high therapeutic effect on the treatment of HBVDNA in PBMC and serum and has better therapeutic effect than that of routine therapy. Lamivudine may also have higher down-regtdated inflananatory infdtration and secretion in local site caused by chemotactic cytokines and produce promotional effect on the recovery of liver function.展开更多
文摘The purpose of this investigation was to study the therapeutic effect of Lamivudine on HBVDNA in peripheral blood mononudear cells （PBMC） and serum, and the level of cytokines in serum of the patients with chronic hepatitis B. The patients were divided into two groups （A = 47, B = 34）, and treated by Lamivudine, routine medicine, respectively. The levels of HBV-DNA in PBMC and serum and eytokines were all detected before and after treatment. After the treatment of Lamivndine for 36 weeks, the total conversion negative rates of HBV-DNA in PBMC and serum of the patients treated with Lamivudine were 55.32% （26/47） and 61.70% （29/47）, respectively. The total negative conversion rates of HBV-DNA in PBMC and serum of the patients treated by routine medicine were 26.47 % （9/34） and 32.35% （11/34）, respectively. There was significant difference between Lamivudine group and routine medicine group （ P 〈 0.01 ）. The negative conversion rates of HBeAg in serum of the patients were 46.81% （22/47） and 68.09% （32/47） at the end of 24 weeks and 36 weeks, and were higher than those of routine medicine group （ P 〈 0.05 and P 〈 0.01 ）. The levels of alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, ALT/AST in serum of the patients after being treated by Lamivudine, routine medicine were down-regulated to （30.1 ± 9.6） U/ml, （32.3 ±10.7） U/ml, 0.9 ±0.1 and （48.4±10.7） U/ml, （44.7 ±11.0） U/ml, 1.1 ±0.2. After the analysis of variance, the high significant difference was obvious between the two groups （ P 〈 0.01）. It was due to the high levels of IL-6, IL-8 and TNF-α in chronic hepatitis B which could be down-regulated to （250.5 ±33.3） pg/ml, （153.4 ±22.2） pg/ml, （232.6 ±21.2） pg/ml by Lamivudine, which was more obvious than that of routine medicine （ P 〈 0.01）. Lamivudine has high therapeutic effect on the treatment of HBVDNA in PBMC and serum and has better therapeutic effect than that of routine therapy. Lamivudine may also have higher down-regtdated inflananatory infdtration and secretion in local site caused by chemotactic cytokines and produce promotional effect on the recovery of liver function.
